Author Archives: Guest Blogger

Pharma M&A: Diverse and Accelerating

By Peter Young. I have been involved with the pharmaceutical and biotech industries, as a strategy consultant with Bain & Company, a venture capitalist with J.H. Whitney, and as an investment banker with Salomon Brothers, Lehman Brothers and Young & Partners. Over that period of time, I have never seen as many different strategies being […]
Posted in Strategy | Leave a comment

European Pharma: Paying the Price of Pharmacovigilance

Pharmacovigilance controls are becoming firmly embedded in the European Union’s post-authorization regulatory system, with the European Medicines Agency (EMA) acting as the pivot for an EU-wide network of agencies monitoring medicines throughout their market lifespan. The new pharmacovigilance activities stemming from the EU legislation, the first stage of which was approved four years ago, relate […]
Posted in Europe, Regulatory, Safety | Tagged , , | Leave a comment

Biopharma's Top Offshore Destinations

Biopharmaceutical manufacturing is following the general pharmaceutical market trend toward global expansion. BioPlan Associates’ 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production identifies the markets best poised to profit from the internationalization of the outsourcing, finding that emerging markets such as China and India are among top potential destinations for both US and Western […]
Posted in Emerging Markets, Global, Guest Blog | Tagged , , | Leave a comment

Sunny Outlook for Outsourcing

Early-stage and mid-size bio/pharmaceutical companies have enjoyed an embarrassment of riches over the past 18 months. The window for initial public offerings (IPOs) re-opened, at least for a while. Global bio/pharmaceutical companies continued their frenzied pace of partnering and acquisition activity, and venture capital spiked up as the prospects improved for rich exits. The results […]
Posted in Global, Guest Blog | Tagged , , | Leave a comment

Healthcare Reform in China: A Doubled-Edge Sword for Foreign Firms?

The Chinese market is attractive to foreign investors for many reasons. It is the world’s third largest market for pharmaceuticals with annual sale of US$71 billion.  In fact, it is poised to become the second largest market in 2015 given that its annual growth rate of sales is between 15 and 20%, according to Yanzhong […]
Posted in Biotech, Emerging Markets, Global, Guest Blog, healthcare, Regulatory | Tagged , | Leave a comment
  • Categories

  • Meta